英文【EFPIA】创新药物不可用和获取延迟的根本原因
The root causes of unavailability of innovative medicines and delay in access The root causes of unavailability of innovative medicines and delay in access: Shortening the wait
报告摘要
The root causes of unavailability of innovative medicines and delay in access The root causes of unavailability of innovative medicines and delay in access: Shortening the wait
核心要点
- 1. The speed of the regulatory process
- 3. Initiation of the process
- 5. Misalignment on evidence requirements
- 2. Accessibility of medicines before marketing
- 4. The speed of national timelines and adherence
- 6. Misalignment on value and price
- 7. The value assigned to product differentiation and
- 8. Insufficient budget to implement decisions
报告信息
- 文件全名
- 《英文【EFPIA】创新药物不可用和获取延迟的根本原因-43页.pdf》
- 适合读者
- 数据来源
- 公开数据综合分析
- 核心议题
常见问题
《英文【EFPIA】创新药物不可用和获取延迟的根本原因》主要包含哪些内容?
The root causes of unavailability of innovative medicines and delay in access The root causes of unavailability of innovative medicines and delay in access: Shortening the wait
这份报告覆盖哪一年、篇幅多大?
覆盖 2025 年,全文约 43。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合战略规划、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了创新药等议题。
继续阅读
查看全部 →